BriaPro subsidiary reports $472K net loss for six months; going concern risk

BriaCell Therapeutics Corp.

BriaPro net loss widened to $472,231 for six months ended Jan 31, 2026 vs $233,185 a year ago.
Accumulated deficit $1.65M; negative working capital $1.64M; cash only $1.
Going concern: dependent on parent BriaCell for financing; material uncertainty noted.
On Feb 18, 2026, BriaPro agreed to acquire sCD80 license from BriaCell for cancer therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.